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tion, where MPR may overstate true adherence. DPR should be
considered when a measure of adherence to a class of medica-
tions is sought, particularly in clinical situations where multiple
medications within a class are often used concurrently.
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OBJECTIVE: The proportion of patients with schizophrenia
considered as being non-compliant with antipsychotic medica-
tions ranges from 20% to 89%. Non-compliance has been asso-
ciated with increase relapse rates, more frequent and longer
hospitalizations. Costs of schizophrenia in the U.S. vary from
$32 to $65 billion, but contradictory results have been reported
for the costs of non-compliance among these patients. The
objective was to estimate the costs of non-compliance with anti-
psychotic medications among patients with schizophrenia.
METHODS: A literature review of studies published in the
last decade was conducted. We utilized PubMed, Cochrane,
EMBASE and CINADHL databases. The key terms included:
(ﬁrst: adherence, non-adherence, compliance, non-compliance),
AND (second: schizophrenia, antipsychotics, atypical and typical
antipsychotics, neuroleptics) AND (third: resource utilization,
resource use, costs, economics, hospitalizations). Studies with
data on costs of non-compliance or compliance were included.
Two independent researchers reviewed the titles and abstracts
and any differences were agreed by consensus. Costs were trans-
formed in 2007 US dollars using the medical care price index.
RESULTS: Of 43 studies, six fulﬁlled the inclusion criteria,
including ﬁve retrospective cohort studies that used Medicaid
paid claims, and a cross-sectional study that used the UK Psychi-
atric Morbidity Survey. Most studies had <3 years of follow-up.
A total of 52,512 participants were studied. The percentage of
non-compliant patients ranged from 11% to 31%. A study found
that users of atypical antipsychotics (72%) have higher compli-
ance than users of typical antipsychotics (56%). Non-compliant
patients spent, on average, ten more days in the hospital, and
have 22% more rehospitalizations than compliant patients.
Costs of care for non-compliant patients were on average $3,104
higher than for compliant patients. CONCLUSION: Patients
non-compliant with antipsychotics had more and longer hos-
pitalizations, and higher total costs than compliant patients.
Non-compliance with antipsychotics has signiﬁcant clinical and
economic implications for patients with schizophrenia.
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OBJECTIVE: To compare time to all-cause discontinuation
(TTAD) across alternative antipsychotics in the treatment of
bipolar disorder (BD). METHODS: Data from a commercial
health plan from July 1, 2003 to June 30, 2006 were used to
identify non-institutionalized patients with bipolar disorder
(ICD-9 296.4–296.8) but no history of schizophrenia (ICD-9
295.xx). Patients initiating treatment using a typical antipsy-
chotic (TAP), atypical antipsychotic (AAP: aripiprazole, olanza-
pine, quetiapine, risperidone or ziprasidone), mood stabilizer or
antidepressant were included. Episodes were divided into three
categories: restarting treatment after a break in drug therapy >15
days with the drug used in the previous episode, switching
therapy with or without a break in treatment, and augmentation
therapy. First observed episodes were excluded from the analysis
due to uncertainty concerning the patient’s prior treatment
history. A total of 106,447 episodes were included in the analyses
using ordinary least squares (OLS) regression models of TTAD
adjusting for age, gender, geographic region, drug use history,
prior medical care use, bipolar disorder diagnosis and co-morbid
medical conditions. RESULTS: Augmentation constituted over
half of all treatment episodes (55.3%) and only 20% of all
episodes included an antipsychotic. Patients initiating augmenta-
tion episodes achieved signiﬁcantly longer TTAD initial therapy
than patients initiating restart (+80 days, p < 0.0001) or switch-
ing episodes (+13 days, p < 0.0001). Moreover, these estimated
differences increased signiﬁcantly when TTAD was measured
over all BD-related therapies (+155 days and +284 respectively).
OLS results comparing initial therapies favored quetiapine,
ziprasidone and aripiprazole relative to TAP in restart (+15 to
+36 days), switching (+18 to +25 days) and augmentation epi-
sodes (+28 to +48 days)(p < 0.05 for 7 of 9 estimates). CON-
CLUSION: In a commercially-insured population, patients with
bipolar disorders initiating therapy using ziprasidone, aripipra-
zole or quetiapine have longer TTAD that TAP patients. Patients
initiating augmentation therapy have much longer TTAD than
other patients, especially when measured across all psychotropic
medications.
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OBJECTIVE: To compare time to all-cause discontinuation
(TTAD) across alternative antipsychotics in the treatment of
schizophrenia. METHODS: Data from a commercial health
plan from July 1, 2003 to June 30, 2006 were used to identify
non-institutionalized patients with schizophrenia (ICD-9 codes
295.xx) who initiated treatment using a typical antipsychotic
(TAP), atypical antipsychotic (AAP: aripiprazole, olanzapine,
quetiapine, risperidone or ziprasidone), mood stabilizer or anti-
depressant. Episodes were divided into three categories: restart-
ing treatment after a break in drug therapy >15 days with the
drug used in the previous episode, switching therapy with or
without a break in treatment, and augmentation therapy. First
observed episodes were excluded from the analysis due to uncer-
tainty concerning the patient’s prior treatment history. A total of
21,872 episodes were included in the analyses using ordinary
least squares (OLS) regression models of TTAD adjusting for age,
gender, geographic region, drug use history, prior medical care
use, schizophrenia diagnosis and co-morbid medical conditions.
RESULTS: Only 39.3% of all episodes involved an antipsychotic.
Antipsychotics were used predominately as augmentation
therapy (55%) with the remaining episodes of antipsychotic drug
therapy evenly divided between restart (23%) and switching
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